Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute myeloid leukemia (AML). In this educational program, these experts present several key abstracts from a recent hematology meeting and recent publications regarding targeted therapies to treat relapsed/refractory AML. Panel discussions about the presented data help learners apply this evidence to personalized treatment plans for patients with AML.
This educational activity is an archive of the live symposium held on April 9, 2026.
Target Audience
This educational activity is directed toward community-based oncologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with AML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the clinical implications of key mechanistic differences between targeted therapies for AML
- Evaluate the latest efficacy and safety data from recent clinical trials of targeted therapies for AML
- Apply emerging evidence into personalized treatment plans for patients with AML based on disease- and patient-specific considerations
Eunice Wang, MD
Chief, Leukemia Service, Vice Chair of Academic Affairs
Dept Medicine
Roswell Park Comprehensive Cancer Center
Professor of Oncology
Jacobs School of Medicine, University of Buffalo
Buffalo NY
Disclosures: Consultant: Kura, Menarini; Scientific Advisory Board: AbbVie, Cullinan, Daiichi Sankyo, Dark Blue Therapeutics, J&J, Kura, Menarini, Novartis, Rigel; Speakers Bureau: Astellas, Dava, Takeda (Education); Grant/Research Funding: Kura, Menarini, Novartis, Rigel; Section Editor: UpToDate
Hetty Carraway, MD, MBA
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University
Vice Chair of Strategy and Enterprise Development
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Agios, BMS, Daiichi, Genentech, Geron, Jazz, Kura, Novartis, Syndax, Takeda; Grant/Research Funding: Celgene; DSMB: Taiho, Takeda; Speakers Bureau: BMS
Naval G. Daver, MD
Professor of Medicine
Co-Lead, Section of AML
Director, Leukemia Research Alliance Program
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agios, Amgen, Arog, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Gilead, ImmunoGen, Jazz, KITE, Novartis, Pfizer, Servier, Shattuck Labs, Stemline/Menarini, Syndax, Trillium; Grant/Research Funding: AbbVie, Amgen, Astellas, Bristol Myers Squibb, Daiichi Sankyo, FATE Therapeutics, Genentech, Gilead, GlycoMimetics, Hanmi, ImmunoGen, KITE, Novimmune, Pfizer, Servier, Trillium, Trovagene
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.